SIGA Technologies (SIGA Technologies) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

SIGA Technologies's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $11.28 Mil.

Hence, SIGA Technologies's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.00.

SIGA Technologies Capex-to-Operating-Income Historical Data

The historical data trend for SIGA Technologies's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Capex-to-Operating-Income Chart

SIGA Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

SIGA Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of SIGA Technologies's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SIGA Technologies's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's Capex-to-Operating-Income falls into.

SIGA Technologies Capex-to-Operating-Income Calculation

SIGA Technologies's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.022)	/	83.621
	=	0.00

SIGA Technologies's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	11.275
	=	0.00

SIGA Technologies (NAS:SIGA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

SIGA Technologies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

SIGA Technologies (SIGA Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 East 62nd Street, New York, NY, USA, 10065

Website

http://www.siga.com

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.

Executives

Evan A. Knisely	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr.	director	4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal	director	30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky	director	35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi	director	35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan	director	C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii	officer: Chief Executive Officer	7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire	officer: Executive VP & CFO	C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas	director	35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane	director	77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby	officer: Chief Scientific Officer	SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer	director	1100 N GLEBE ROAD, ARLINGTON VA 22201